Quinteros A Roxanna, Fica C Alberto, Abusada A Nancy, Muñoz C Lorena, Novoa M Catalina, Gallardo A Carlos
Servicio de Infectología, Hospital Militar de Santiago, Chile.
Rev Chilena Infectol. 2010 Feb;27(1):25-33. Epub 2010 Feb 3.
Amphotericin B deoxycholate is associated with infusion-related toxicity and renal toxicity.
To evaluate medical indications of this compound in a tertiary care center, analyze adverse reactions, infusion protocols and outcome of treated patients.
Retrospective analysis of 39 treatments indicated in 33 patients during 2007, exploring indications, infusion protocols and renal protective measures, infusion-related adverse reactions, nephrotoxicity, hypokalemia and outcomes.
On average, therapy lasted 12 days (2 to 39) and reached 600 mg of accumulated dose (100 to 1950) respectively. 24-hours infusions were applied in 63.2% of prescriptions and 35.9% received a 4-6 hour infusion schedule. In addition, 36.8% received daily a saline infusion before amphotericin. Adverse reactions were observed in 40% of treatments, predominating fever (25%). Nonetheless, nephrotoxicity was infrequent (9.4%), of low magnitude, only affecting patients without previous renal disease, and not requiring dialysis. Hypokalemia developed in 21.6% of treatments. More than half of medical indications were empirical (59%), for presumed infections by either filamentous fungi or yeasts. In the subgroup with microbiological information, main indications were invasive aspergillosis (15.4% of total), systemic candidiasis (12.8%) or meningeal cryptococcosis (10.3%). A favorable response was registered in 41%, and only 48.5% of patients survived. In a multivariate analysis, only age > 60 years remained as an independent factor for developing infusion-related adverse reactions. In the same manner, a SOFA score > 3 and corticosteroids administration at the same time than amphotericin B, were independently associated to a fatal outcome.
infusion-related adverse reactions are frequent during amphotericin B deoxycholate therapy, but renal toxicity is occasionally observed. Amphotercin B was used mainly as empirical therapy in this study.
两性霉素B脱氧胆酸盐与输注相关毒性和肾毒性有关。
评估该化合物在三级医疗中心的医学适应证,分析不良反应、输注方案及治疗患者的结局。
回顾性分析2007年33例患者的39次治疗,探究适应证、输注方案及肾脏保护措施、输注相关不良反应、肾毒性、低钾血症及结局。
平均治疗持续12天(2至39天),累积剂量分别达到600毫克(100至1950毫克)。63.2%的处方采用24小时输注,35.9%接受4至6小时的输注方案。此外,36.8%的患者在使用两性霉素之前每日接受生理盐水输注。40%的治疗观察到不良反应,主要为发热(25%)。然而,肾毒性不常见(9.4%),程度较轻,仅影响既往无肾脏疾病的患者,且无需透析。21.6%的治疗出现低钾血症。超过一半的医学适应证为经验性用药(59%),用于推测由丝状真菌或酵母菌引起的感染。在有微生物学信息的亚组中,主要适应证为侵袭性曲霉病(占总数的15.4%)、系统性念珠菌病(12.8%)或脑膜隐球菌病(10.3%)。41%的患者有良好反应,仅48.5%的患者存活。在多变量分析中,仅年龄>60岁是发生输注相关不良反应的独立因素。同样,序贯器官衰竭评估(SOFA)评分>3以及在使用两性霉素B的同时给予皮质类固醇与致命结局独立相关。
两性霉素B脱氧胆酸盐治疗期间输注相关不良反应常见,但偶尔观察到肾毒性。在本研究中,两性霉素B主要用作经验性治疗。